A Phase I, Single Center, Open-label, Dose Escalation Study of Recombinant Human Granulocyte Colony-stimulating Factor Fc Fusion Protein (F-627) in Breast Cancer Patient Receiving Adjuvant Chemotherapy

Next Previous
Trial Profile

A Phase I, Single Center, Open-label, Dose Escalation Study of Recombinant Human Granulocyte Colony-stimulating Factor Fc Fusion Protein (F-627) in Breast Cancer Patient Receiving Adjuvant Chemotherapy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Aug 2015

At a glance

  • Drugs Benegrastim (Primary) ; Cyclophosphamide; Epirubicin
  • Indications Breast cancer
  • Focus Adverse reactions
  • Sponsors Generon (Shanghai) Corporation

    • Most Recent Events

    • 23 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top